右美托咪定用于成人心脏手术:系统综述、荟萃分析与试验序贯分析
该系统综述与荟萃分析纳入48项随机对照试验共6273例成人心脏手术患者,评估围术期右美托咪定效果。右美托咪定缩短ICU停留5.0小时和气管插管1.6小时,降低术后谵妄、房颤和短期死亡率风险,但校正可能虚假数据后效果减弱。
要点
- 围术期右美托咪定缩短成人心脏手术后ICU停留和气管插管时间。
- 右美托咪定降低术后谵妄、房颤和短期死亡率风险。
- 校正可能虚假数据后,ICU和插管时间缩短幅度减小。
核心结论
- 围术期右美托咪定缩短成人心脏手术后ICU停留和气管插管时间,并降低短期死亡率。
- ICU停留和气管插管时间的缩短可能或不一定具有临床意义,尤其在校正可能虚假数据后。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE via Pubmed、EMBASE、Scopus和Cochrane 1990年1月1日至2022年3月1日的随机对照试验。
- 纳入48项试验共6273例参与者,使用Joanna Briggs Institute方法学清单评估研究质量,GRADE方法评估证据确定性。
- 采用随机效应荟萃分析主要结局:ICU停留时间和气管插管时间。
主要发现
- 右美托咪定减少平均ICU停留时间5.0(95%CI 2.2-7.7)小时,p=0.001。
- 右美托咪定减少平均气管插管时间1.6(95%CI 0.6-2.7)小时,p=0.003。
- 术后谵妄相对风险0.58(95%CI 0.43-0.78),p=0.001。
- 房颤相对风险0.76(95%CI 0.61-0.95),p=0.015。
- 短期死亡率相对风险0.49(95%CI 0.25-0.97),p=0.041。
关键数值与推荐
- 心动过缓和低血压无显著影响。
- 试验序贯分析与主要荟萃分析一致。
- 校正可能虚假数据后,ICU停留时间减少降至3.6(95%CI 1.8-5.4)小时,气管插管时间减少降至0.8(95%CI 0.2-1.4)小时。
- 以Joanna Briggs Institute评分阈值10进行方法学质量的二元校正未显著改变结果。
临床怎么用
- 成人心脏手术围术期可考虑使用右美托咪定以缩短ICU停留和气管插管时间。
- 右美托咪定可能降低术后谵妄、房颤和短期死亡率风险。
- 临床获益程度需结合校正虚假数据后的效果谨慎评估。
局限性
- 校正可能虚假数据后,ICU停留和气管插管时间缩短幅度减小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The effects of dexmedetomidine in adults undergoing cardiac surgery are inconsistent. We conducted a systematic review and meta-analysis to analyse the effects of peri-operative dexmedetomidine in adults undergoing cardiac surgery. We searched MEDLINE via Pubmed, EMBASE, Scopus and Cochrane for relevant randomised controlled trials between 1 January 1990 and 1 March 2022. We used the Joanna Briggs Institute methodology checklist to assess study quality and the GRADE approach to certainty of evidence. We assessed the sensitivity of results to false data. We used random-effects meta-analyses to analyse the primary outcomes: durations of intensive care and tracheal intubation. We included 48 trials of 6273 participants. Dexmedetomidine reduced the mean (95%CI) duration of intensive care by 5.0 (2.2-7.7) h, p = 0.001, and tracheal intubation by 1.6 (0.6-2.7) h, p = 0.003. The relative risk (95%CI) for postoperative delirium was 0.58 (0.43-0.78), p = 0.001; 0.76 (0.61-0.95) for atrial fibrillation, p = 0.015; and 0.49 (0.25-0.97) for short-term mortality, p = 0.041. Bradycardia and hypotension were not significantly affected. Trial sequential analysis was consistent with the primary meta-analysis. Adjustments for possible false data reduced the mean (95%CI) reduction in duration of intensive care and tracheal intubation by dexmedetomidine to 3.6 (1.8-5.4) h and 0.8 (0.2-1.4) h, respectively. Binary adjustment for methodological quality at a Joanna Briggs Institute score threshold of 10 did not alter the results significantly. In summary, peri-operative dexmedetomidine reduced the durations of intensive care and tracheal intubation and the incidence of short-term mortality after adult cardiac surgery. The reductions in intensive care stay and tracheal intubation may or may not be considered clinically useful, particularly after adjustment for possible false data.
引用
- Poon WH, Ling RR, Yang IX, et al. Dexmedetomidine for adult cardiac surgery: a systematic review, meta-analysis and trial sequential analysis. Anaesthesia. 2022. PMID: 36535747. doi:10.1111/anae.15947
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。